Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22996497 | 0.86 | AGBL2 (0.40) | AGBL2SMN1; SMN2HCAR2CYP1A2MAOB | |
| SCHEMBL1759837 | 0.81 | NAPRT (0.48) | AGBL2HCAR2NAPRTCES2CES1 | |
| SCHEMBL31356591 | 0.80 | OPRK1 (0.42) | SMN1; SMN2HCAR2CYP1A2MAOBMAOA | |
| SCHEMBL9928617 | 0.80 | AGBL2 (0.39) | AGBL2SMN1; SMN2HCAR2CYP1A2MAOB | |
| SCHEMBL27861146 | 0.80 | AGBL2 (0.39) | AGBL2SMN1; SMN2HCAR2CYP1A2MAOB | |
| SCHEMBL9648890 | 0.80 | OPRK1 (0.42) | SMN1; SMN2HCAR2CYP1A2MAOBMAOA | |
| SCHEMBL31382799 | 0.80 | PIK3C3 (0.39) | AGBL2SMN1; SMN2HCAR2CYP1A2MAOB | |
| SCHEMBL4874417 | 0.80 | PIK3C3 (0.39) | AGBL2SMN1; SMN2HCAR2CYP1A2MAOB | |
| SCHEMBL29920919 | 0.79 | DGAT1 (0.41) | AGBL2HCAR2 | |
| SCHEMBL15636128 | 0.79 | OPRK1 (0.48) | AGBL2SMN1; SMN2ALDH1A1KDM4EOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751887-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751887-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751887-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2857404-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| EP-2857404-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9187489-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187489-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187489-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| EP-2857404-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857404-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | AGBL2 2826/4885SMN1; SMN2 2475/4885HCAR2 2935/4885 |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | AGBL2 2826/4885SMN1; SMN2 2475/4885HCAR2 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.